GlassScriptPhysician profile
Kenneth D Abreo
NPI 1750303145
$42,482.17
in general payments reported to CMS, 2019-2025
26 companies · $1,408 in 2025
The $1,408 reported for 2025 was more than what 85% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
See the full distribution for Nephrology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $774 · 2020: $624 · 2021: $619 · 2022: $4,980 · 2023: $30K · 2024: $4,226 · 2025: $1,408.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Honoraria: $29K · Food and Beverage: $3,667 · Travel and Lodging: $2,534 · Education: $83.54.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Honoraria | $29,200.00 |
| Food and Beverage | $3,666.61 |
| Travel and Lodging | $2,534.38 |
| Education | $83.54 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Calliditas Therapeutics US INC. | $36,761.46 | 2022-2025 | Tarpeyo |
| Astrazeneca Pharmaceuticals LP | $1,088.23 | 2019-2025 | Lokelma, Farxiga |
| Otsuka America Pharmaceutical, INC. | $931.14 | 2019-2025 | Jynarque |
| Mallinckrodt Hospital Products INC. | $595.11 | 2020-2025 | Acthar, Terlivaz |
| Amgen INC. | $365.24 | 2019-2025 | Tavneos |
| Fresenius USA Marketing, INC. | $363.75 | 2019-2025 | Velphoro, Velphoro |
| Travere Therapeutics, INC. | $361.24 | 2024-2025 | |
| Aurinia Pharma U.S., INC. | $218.61 | 2022-2023 | Lupkynis |
| Nxstage Medical, INC. | $205.05 | 2021-2025 | Nxstage System One, Liberty Select Cycler |
| Glaxosmithkline, LLC. | $188.04 | 2021-2023 | Benlysta |
| Alexion Pharmaceuticals, INC. | $176.15 | 2022-2025 | Ultomiris |
| Novartis Pharmaceuticals Corporation | $164.08 | 2024-2025 | |
| Daiichi Sankyo INC. | $160.91 | 2019-2024 | Injectafer |
| Vifor Pharma, INC. | $153.82 | 2019-2023 | Veltassa |
| Mallinckrodt Enterprises LLC | $125.28 | 2019 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Horizon Therapeutics Plc | $124.99 | 2023 | Krystexxa |
| W. L. Gore & Associates, INC. | $124.47 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $116.17 | 2021-2025 | |
| Av Medical Technologies LTD. | $72.04 | 2019 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $45.77 | 2024 | |
| Covidien LP | $38.80 | 2019 | |
| Akebia Therapeutics INC | $32.80 | 2021-2022 | |
| Opko Pharmaceuticals, LLC | $19.94 | 2025 | Rayaldee |
| Genzyme Corporation | $18.61 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $18.57 | 2024 | Jardiance |
| Genentech USA, INC. | $11.90 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kenneth Abreo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.